AI 본문요약

엑셀 다운로드 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

질의응답

참고문헌 (77)

1. Friis-Hansen B. Water distribution in the foetus and newborn infant. Acta Peadiatr Scand Suppl 1983;305:7-11. 

2. Pai VB, Nahata MC. Drug dosing in pediatric patients. In: Murphy JE, ed. Clinical pharmacokinetics. 5th ed. Bethesda, MD: Am Soc Healthsyst Pharm; 2011:29-44. 

3. Vanpee M, Blennow M, Linne T, Herin P, Aperia A. Renal function in very low birth weight infants: normal maturity reached during early childhood. J Pediatr 1992;121:784-8. 

   상세보기

4. Kearns GL. Pharmacogenetics and development: are infants and children at increased risk for adverse outcomes? Curr Opin Pediatr 1995;7:220-33. 

   상세보기

5. Taketomo CK, Hodding JH, Kraus DM. Pediatric & Neonatal Dosage Handbook, 22th ed. Hudson, OH: Lexi-Comp, 2015 

6. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Clin Pharmacokinet 1980;5:485-527. 

   상세보기

7. Besunder JB, Reed MD, Blumer JL. Principles of drug disposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface. Clin Pharmacokinet 1988;14:189-216 

   상세보기

8. Friedman CA, Parks BR, Rawson JE. Gentamicin disposition in asphyxiated newborns: relationship to mean arterial pressure and urine output. Pediatr Pharmacol (New York)1982;2:189-97. 

9. Touw DJ, Graafland O, Cranendonk A, Vermeulen RJ, van Weissenbruch MM. Clinical pharmacokinetics of phenobarbital in neonates. Eur J Pharm Sci 2000;12(2):111-6. 

   상세보기

10. Donn SM, Grasela TH, Goldstein, GW. Safety of a Higher Loading Dose of Phenobarbital in the Term Newborn. Pediatrics 1985;75(6):1061-4. 

    상세보기

11. Heimann G, Galdtke E. Pharmacokinetics of Phenobarbital in Childhood. Eur J Clin Pharmacol 1977;12(4):305-10. 

    상세보기

12. Yukawa M, Yukawa E, Suematsu F, et al. Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. J Clin Pharm Ther 2011;36(6):704-10. 

    상세보기

13. Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B, Simon N. Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. Fundam Clin Pharmacol 2014;28(4):465-71. 

    상세보기

14. Lee SM, Chung JY, Lee YM, et al. Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child 2012;97(6):569-72. 

    상세보기

15. van den Broek MP, Groenendaal F, Toet MC, et al. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. Clin Pharmacokinet 2012;51(10):671-9. 

    상세보기

16. Shellhaas RA, Ng CM, Dillon CH, Barks JD, Bhatt-Mehta V. Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr Crit Care Med 2013;14(2):194-202. 

    상세보기

17. Filippi L, la Marca G, Cavallaro G, et al. Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. Epilepsia 2011;52(4):794-801. 

    상세보기

18. Pitlick W, Painter M, Pippenger C. Phenobarbital pharmaockinetics in neonates. Clin P harmacol Ther 1978;23(3):346-50. 

    상세보기

19. Grasela TH Jr, Donn SM. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data. Dev Pharmacol Ther 1985;8(6):374-83. 

    상세보기

20. Kim SE, Kim BH, Lee S, et al. Population pharmacokinetics of theophylline in premature Korean infants. Ther Drug Monit 2013;35(3):338-44. 

    상세보기

21. Fukuda T, Yukawa E, Kondo G, et al. Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea. J Clin Pharm Ther 2005;30(6):591-6. 

    상세보기

22. Jones RA, Baillie E. Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. Arch Dis Child 1979;54(3):190-3. 

    상세보기

23. Dothey CI, Tserng KY, Kaw S, King KC. Maturational changes of theophylline pharmacokinetics in preterm infants. Clin Pharmacol Ther 1989;45(5):461-8. 

    상세보기

24. Aranda JV, Turmen T, Sasyniuk BI. Pharmacokinetics of diuretics and methylxanthines in the neonate. Eur J Clin Pharmacol 1980;18(1):55-63. 

    상세보기

25. Brazier JL, Renaud H, Ribon B, Salle BL. Plasma xanthine levels in low birth weight infants treated or not treated with theophylline. Arch Dis Child 1979;54(3):194-9. 

    상세보기

26. Islam SI, Ali AS, Sheikh AA, Fida NM. Pharmacokinetics of theophylline in preterm neonates during the first month of life. Saudi Med J 2004;25(4):459-65. 

    상세보기

27. Moore ES, Faix RG, Banagale RC, Grasela TH. The population pharmacokinetics of theophylline in neonates and young infants. J Pharmacokinet Biopharm. 1989 Feb;17(1):47-66. 

    상세보기

28. Young TE, Mangum B. Neofax. 24th ed. Thomson Reuters, 2011 

29. Pacifici GM. Clinical pharmacokinetics of aminoglycosides in neonates: a review. Eur J Clin Pharmacol 2009;65:419-427. 

    상세보기

30. Olavarria F, Dolz H, Krause S, et al. Torres T, Influence of gestational age and postnatal kidney maturation on the kinetics of gentamicin. Rev Chil Pediatr 1990;61(2):86-90. 

31. An SH, Kim JY, Gwak HS. Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. Am J Health-Syst Pharm 2014;71:122-7. 

    상세보기

32. Treluyer JM, Merle Y, Tonnelier S, et al. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants and children. Antimicrob Agents Chemother 2002; 46:1381-7. 

    상세보기

33. Allegaert K, Anderson BJ, Cossey V et al. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 2006;61:39-48. 

    상세보기

34. Peterson PO, Wells TG, Kearns GL. Amikacin dosing in neonates: evaluation of a dosing chart based on population pharmacokinetic data. Dev Pharmacol Ther 1991;16:203-11. 

35. Nielsen EI, Sandstrom M, Honore PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modeling of a prospective study. Clin Pharmacokinet 2009;48(4):253-63. 

    상세보기

36. McDougal A, Ling EW, Levine M. Vancomycin pharmacokinetics and dosing in premature neonates. Ther Drug Monit 1995;17(4):319-26. 

    상세보기

37. Lulic-Botica M, Sheer T, Edwards D, Thomas RL, Natarajan G. Impact of small-for-gestational age (SGA) status on gentamicin pharmacokinetics in neonates. J Clin Pharmacol 2014;54(1):39-45. 

    상세보기

38. Radde IC. Renal function and elimination of drugs during development. In: Radde IC, Macleod SM, eds. Pediatric pharmacology and Therapeutics. St. Louis: Mosby-Tear Book. 1993;87. 

39. deHoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 2004;43(7):417-40. 

    상세보기

40. James A, Koren G, Milliken J, Soldin S, Prober C. Vancomycin pharmacokinetics and dose recommendations for preterm infants. Antimicrob Agents Chemother 1987;31(1):52-4. 

    상세보기

41. Jarrett RV, Marinkovich GA, Gayle EL, Bass JW. Individualized pharmacokinetic profiles to compute vancomycin dosage and dosing interval in preterm infants. Pediatr Infect Dis J 1993;12(2):156-7. 

    상세보기

42. Rodvold KA, Gentry CA, Plank GS, Kraus DM, Nickel E, Gross JR. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995;17(3):239-46. 

    상세보기

43. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24:67-76. 

    상세보기

44. Kildoo CW, Lin LM, Gabriel MH, Folli HL, Modanlou HD. Vancomycin pharmacokinetics in infants: relationship to postconceptional age and serum creatinine. Dev Pharmacol Ther 1989;14(2):77-83. 

45. Grimsley C, Thomson AH. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch Dis Child Fetal Neonatal Ed 1999;81(3):F221-7. 

    상세보기

46. Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol 2001;41(9):927-34. 

    상세보기

47. Frymoyer A, Meng L, Bonifacio SL, Verotta D, Guglielmo BJ. Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy 2013; 33(7):718-26. 

    상세보기

48. Gilman JT, Gal P, Levine RS, Hersh CB, Erkain NV. Factors influencing theophylline disposition in 179 newborns. Ther Drug Monit 1986;8(1):4-10. 

    상세보기

49. Gal P, Toback J, Erkan NV, Boer HR. The influence of asphyxia on phenobarbital dosing requirements in neonates. Dev Pharmacol Ther 1984;7(3):145-52. 

    상세보기

50. Gal P, Boer HR, Toback J, Wells TJ, Erkan NV. Effect of asphyxia on theophylline clearance in newborns. South Med J 1982;75(7):836-8. 

    상세보기

51. Friedman CA, Parks BR, Rawson JE. Gentamicin disposition in asphyxiated newborns: relationship to mean arterial blood pressure and urine output. Pediatr Pharmacol (New York) 1982;2(3):189-97. 

    상세보기

52. Zanelli S, Buck M, Fairchild K. Physiologic and pharmacologic considerations for hypothermia therapy in neonates. J Perinatol 2011; 31(6):377-86. 

    상세보기

53. Van den Broek MPH, Groenendaal F, Egberts ACG, et al. Effects of hypothermia on pharmacokinetics and pharmacodynamics. Clin Pharmacokin 2010; 49:277-94. 

    상세보기

54. Mark LF, Solomon A, Northington FJ, Lee CK. Gentamicin pharmacokinetics in neonates undergoing therapeutic hypothermia. Ther Drug Monit 2013;35:217-22. 

    상세보기

55. Ting JY, Kwan E, McDougal A, Osiovich H. Pharmacokinetics of gentamicin in newborns with moderate-to-severe hypoxicischemic encephalopathy undergoing therapeutic hypothermia. Ind J Pediatr 2015;82:119-25. 

    상세보기

56. Frymoyer A, Bonifacio SL, Drover DR, et al. Decreased Morphine Clearance in Neonates With Hypoxic Ischemic Encephalopathy Receiving Hypothermia. J Clin Pharmacol 2017;57(1):64-76. 

    상세보기

57. Cies JJ, Fugarolas KN, Moore WS, Mason RW, Menkiti OR. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia. Pharmacotherapy 2017;37(4):456-63. 

    상세보기

58. Bartlett RH, Gazzaniga AB, Toomasian J, Coran AG, Roloff D, Rucker R. Extracorporeal membrane oxygenation (ECMO) in neonatal respiratory failure. 100 cases. Ann Surg 1986;204(3):236-45. 

    상세보기

59. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation; Implications for drug therapy of neonates. Clin Pharmacokinet 2003;42(5):403-17. 

    상세보기

60. Marasco SF, Lukas G, McDonald M, McMillan J, Ihle B. Review of ECMO (extra corporeal membrane oxygenation) support in critically ill adult patients. Heart Lung Circ 2008;17(Suppl 4):S41-7. 

61. Lawson G, Mulla H, Upton DR, Firmin RK. Drug disposition during extracorporeal membrane oxygenation (ECMO). Paediatric Perinatal Drug Ther 2001;4:109-20. 

62. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF. Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. Pediatr Infect Dis J 1990;9(8):562-6. 

63. Dodge WF, JelliffeRW, Zwischenberger JB, Bellanger RA, Hokanson JA, Snodgrass WR. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994;16(6):552-9. 

    상세보기

64. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 1996;40:1139-42. 

    상세보기

65. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998;18(5):1082-6. 

    상세보기

66. Geiduschek JM, Lynn AM, Bratton SL, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med 1997;25:360-4. 

    상세보기

67. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med 2005;31:257-63. 

    상세보기

68. Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet 2010;49:407-19. 

    상세보기

69. Ahsman MJ, Wildschut ED, Tibboel D, Mathot RA. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother 2010; 54:1734-41. 

    상세보기

70. Wildschut ED, Ahsman MJ, Houmes RJ, et al. Pharmacotherapy in neonatal and pediatric extracorporeal membrane oxygenation (ECMO). Curr Drug Metab 2012;13:767-77. 

    상세보기

71. Williams BS, Ransom JL, Gap P, et al. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. Crit Care Med 1997;25:273-275. 

    상세보기

72. Watterberg KL, Kelly HW, Johnson JD, Aldrich M, Angelus P. Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (less than 1,500 g) babies. Dev Pharmacol Ther 1987;10(2):107-17. 

    상세보기

73. Gal P, Ransom JL, Weaver RL. Gentamicin in neonates: the need for loading dose. Am J Perinatol 1990;7:254-7. 

    상세보기

74. Touw DJ, Proost JH, Stevens R, Lafeber HN, van Weissenbruch MM. Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus. Pharm World Sci 2001;23(5):200-4. 

    상세보기

75. Zarfin Y, Koren G, Maresky D, Perlman M, MacLeod S. Possible indomethacin-aminoglycoside interaction in preterm infants. J Pediatr 1985;106(3):511-3. 

    상세보기

76. Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. J Matern Fetal Neonatal Med 2009;22(Suppl 3):88-91. 

    상세보기

77. Matic M, Norman E, Rane A, et al. Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Pharmacogenomics 2014;15(12):1589-97. 

    상세보기

저자의 다른 논문 :

안숙희 (8)